PL-17 risk and management of thrombosis in multiple myeloma

Thrombosis Research

Volumn 129, Issue SUPPL. 1, 2012, Pages

  Leebeek, Frank W G ^a   Kruip, Marieke J H A ^a   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulants; Arterial thrombosis; Aspirin; LMWH; Multiple myeloma; Venous thrombosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ARTERY THROMBOSIS; CONFERENCE PAPER; FIBRINOLYSIS; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; REVIEW; RISK MANAGEMENT;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HUMANS; MULTIPLE MYELOMA; RISK MANAGEMENT; THROMBOSIS;

EID: 84862133659     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(12)70024-5     Document Type: Conference Paper

References (56)

1. A Palumbo, K Anderson Multiple myeloma N Engl J Med 364 2011 1046 1060
2. M Zangari, F Elice, L Fink, G Tricot Thrombosis in multiple myeloma Expert Rev Anticancer Ther 7 2007 307 315 (Pubitemid 46488336)
3. SY Kristinsson, RM Pfeiffer, M Bjorkholm, LR Goldin, S Schulman, C Blimark et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study Blood 115 2010 4991 4998
4. A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, B Barlogie et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2008 414 423 (Pubitemid 351255436)
5. B Barlogie, S Jagannath, KR Desikan, S Mattox, D Vesole, D Siegel et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 93 1999 55 65 (Pubitemid 29019388)
6. M Zangari, E Siegel, B Barlogie, E Anaissie, F Saghafifar, A Fassas et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy Blood 100 2002 1168 1171 (Pubitemid 34864267)
7. M Zangari, G Tricot, L Polavaram, F Zhan, A Finlayson, R Knight et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone J Clin Oncol 28 2010 132 135
8. B Barlogie, R Desikan, P Eddlemon, T Spencer, J Zeldis, N Munshi et al. Extended survival in advanced and refractory multiple myeloma after singleagent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients Blood 98 2001 492 494
9. M Zangari, B Barlogie, R Thertulien, J Jacobson, P Eddleman, L Fink et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival Clin Lymphoma 4 2003 32 35 (Pubitemid 36826874)
10. MA Dimopoulos, K Zervas, G Kouvatseas, E Galani, V Grigoraki, C Kiamouris et al. Thalidomide and dexamethasone combination for refractory multiple myeloma Ann Oncol 12 2001 991 995 (Pubitemid 32725775)
11. A Abdelkefi, L Torjman, N Ben Romdhane, S Ladeb, H El Omri, T Ben Othman et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma Bone Marrow Transplant 36 2005 193 198 (Pubitemid 41136290)
12. C Rus, M Bazzan, A Palumbo, S Bringhen, M Boccadoro Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis J Thromb Haemost 2 2004 2063 2065 (Pubitemid 40192769)
13. A Palumbo, S Bringhen, T Caravita, E Merla, V Capparella, V Callea et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 2006 825 831 (Pubitemid 43363369)
14. M Zangari, B Barlogie, E Anaissie, F Saghafifar, P Eddlemon, J Jacobson et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation Br J Haematol 126 2004 715 721 (Pubitemid 39221309)
15. M Carrier, G Le Gal, J Tay, C Wu, AY Lee Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis J Thromb Haemost 9 2011 653 663
16. LK Hicks, MC Cheung, K Ding, B Hasan, L Seymour, A Le Maitre et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials Cancer 115 2009 5516 5525
17. M Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, A Dmoszynska et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2007 2123 2132 (Pubitemid 350146107)
18. S Lonial, PG Richardson, J San Miguel, P Sonneveld, MW Schuster, J Blade et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma Br J Haematol 143 2008 222 229
19. PG Richardson, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, T Facon et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma Br J Haematol 137 2007 429 435 (Pubitemid 46698286)
20. M Zangari, L Fink, F Zhan, G Tricot Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens Clin Lymphoma Myeloma Leuk 11 2011 228 236
21. M Galli, F Elice, C Crippa, B Comotti, F Rodeghiero, T Barbui Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma Haematologica 89 2004 1141 1142 (Pubitemid 39295488)
22. SA Schey, J Cavenagh, R Johnson, JA Child, H Oakervee, RW Jones An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment Leuk Res 27 2003 909 914 (Pubitemid 36809087)
23. W Raven, A Berghout, A van Houten, FW Leebeek Treatment of multiple myeloma and arterial thrombosis Ann Hematol 89 2010 419 420
24. EJ Libourel, P Sonneveld, B van der Holt, MP de Maat, FW Leebeek High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study Blood 116 2010 22 26
25. M Cavo, E Zamagni, C Cellini, P Tosi, D Cangini, M Cini et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy Blood 100 2002 2272 2273 (Pubitemid 35001274)
26. CT Esmon Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis Baillieres Clin Haematol 7 1994 453 468 (Pubitemid 24296874)
27. MC Minnema, R Fijnheer, PG De Groot, HM Lokhorst Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment J Thromb Haemost 1 2003 445 449
28. B Jilma, T Cvitko, A Winter-Fabry, K Petroczi, P Quehenberger, AD Blann High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men Thromb Haemost 94 2005 797 801 (Pubitemid 41489240)
29. LL Swystun, LY Shin, S Beaudin, PC Liaw Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes J Thromb Haemost 7 2009 619 626
30. F Avcu, AU Ural, T Cetin, O Nevruz Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro Thromb Res 121 2008 567 571 (Pubitemid 351174280)
31. Y Shen, X Zhou, Z Wang, G Yang, Y Jiang, C Sun et al. Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma Leuk Res 35 2011 147 151
32. M Zangari, J Guerrero, F Cavallo, HK Prasad, D Esseltine, L Fink Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma Haematologica 93 2008 953 954 (Pubitemid 351821742)
33. EJ Anaissie, EA Coleman, JA Goodwin, RL Kennedy, KD Lockhart, CB Stewart et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis Cancer 2011
34. F Elice, L Fink, G Tricot, B Barlogie, M Zangari Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism Br J Haematol 134 2006 399 405 (Pubitemid 44079553)
35. JJ Auwerda, P Sonneveld, MP de Maat, FW Leebeek Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma Haematologica 92 2007 279 280 (Pubitemid 46852441)
36. AM van Marion, JJ Auwerda, T Lisman, P Sonneveld, MP de Maat, HM Lokhorst et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens Leuk Res 32 2008 1078 1084
37. FR Rickles, S Patierno, PM Fernandez Tissue factor, thrombin, and cancer Chest 124 2003 58S 68S (Pubitemid 37128437)
38. HF Negaard, PO Iversen, B Ostenstad, N Iversen, PA Holme, PM Sandset Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor Thromb Haemost 99 2008 1040 1048 (Pubitemid 351810485)
39. AB Santos, P Llamas, A Roman, E Prieto, R De Ona, JF De Velasco et al. Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt Br J Haematol 122 2003 159 160 (Pubitemid 36819351)
40. T Lisman, PG de Groot, JC Meijers, FR Rosendaal Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis Blood 105 2005 1102 1105 (Pubitemid 40170881)
41. AH Guimaraes, EL de Bruijne, T Lisman, DW Dippel, JW Deckers, D Poldermans et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age Br J Haematol 145 2009 115 120
42. AM van Marion, JJ Auwerda, MC Minnema, R van Oosterom, J Adelmeijer, PG de Groot et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis Thromb Haemost 94 2005 1341 1343 (Pubitemid 41819641)
43. ME Tesselaar, FP Romijn, IK Van Der Linden, FA Prins, RM Bertina, S Osanto Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5 2007 520 527 (Pubitemid 46680685)
44. AK Kakkar, NR Lemoine, MF Scully, S Tebbutt, RC Williamson Tissue factor expression correlates with histological grade in human pancreatic cancer Br J Surg 82 1995 1101 1104
45. JJ Auwerda, Y Yuana, S Osanto, MP de Maat, P Sonneveld, RM Bertina et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma Thromb Haemost 105 2011 14 20
46. DC Johnson, S Corthals, C Ramos, A Hoering, K Cocks, NJ Dickens et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping Blood 112 2008 4924 4934
47. SY Kristinsson Thrombosis in multiple myeloma Hematology Am Soc Hematol Educ Program 2010 2010 437 444
48. D Weber, K Rankin, M Gavino, K Delasalle, R Alexanian Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 2003 16 19
49. MC Minnema, I Breitkreutz, JJ Auwerda, B van der Holt, FW Cremer, AM van Marion et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy Leukemia 18 2004 2044 2046 (Pubitemid 40028434)
50. R Baz, L Li, K Kottke-Marchant, G Srkalovic, B McGowan, E Yiannaki et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma Mayo Clin Proc 80 2005 1568 1574 (Pubitemid 41747058)
51. A Palumbo, M Cavo, S Bringhen, E Zamagni, A Romano, F Patriarca et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial J Clin Oncol 29 2011 986 993
52. A Larocca, F Cavallo, S Bringhen, F Di Raimondo, A Falanga, A Evangelista et al. Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide Blood 2011
53. JA Snowden, SH Ahmedzai, J Ashcroft, S D'Sa, T Littlewood, E Low et al. Guidelines for supportive care in multiple myeloma 2011 Br J Haematol 154 2011 76 103
54. AY Lee, MN Levine, RI Baker, C Bowden, AK Kakkar, M Prins et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146 153 (Pubitemid 36818784)
55. RD Hull, GF Pineo, RF Brant, AF Mah, N Burke, R Dear et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer Am J Med 119 2006 1062 1072 (Pubitemid 44826932)
56. C Ay, D Dunkler, R Simanek, J Thaler, S Koder, C Marosi et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study J Clin Oncol 29 2011 2099 2103